✦ LIBER ✦

Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Laurie, S.A; Miller, V.A; Johnson, D; Ng, K.K; Heelan, R.T; Pizzo, B.A; Perez, W.J; Kris, M.G; Ochs, J; Averbuch, S

Book ID: 118569775
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 116 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80230-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Objective regressions in non-small cell

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

✍ Kris, M.G; Herbst, R; Rischin, D; LoRusso, P; Baselga, J; Hammond, L; Feyereislo 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Antitumor activity of the epidermal grow

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Pretreatment Epidermal Growth Factor Rec

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer

✍ Su, K.-Y.; Chen, H.-Y.; Li, K.-C.; Kuo, M.-L.; Yang, J. C.-H.; Chan, W.-K.; Ho, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 676 KB

PCN109 Cost Effectiveness of First Line

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

✍ Borget, I.; Vergnenegre, A.; Chouaid, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

53 A phase I study of epidermal growth f

53 A phase I study of epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC)

✍ C. Bokemeyer; C. Kollmannsberger; M. Schittenhelm; F. Honecker; H.J. Ahrens; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 334 KB

Do We Really Need Another Epidermal Grow

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?

✍ Haspinger, E. R.; Garassino, M. C.; Torri, V.; Cinquini, M.; De Braud, F.; Gelso 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 78 KB